Annexin Q2: Positioned to advance: DR study and BD efforts
18 juli, 08:42
18 juli, 08:42
Redeye comments on Annexin’s Q2 report and recent events in the company. Following the Q1 report, we implemented several updates to our model. With the Q2 figures now incorporated, only minor housekeeping adjustments have been made. The company is expected to initiate a phase IIa study in diabetes-induced retinopathy shortly, with potential for top-line data before year-end. Meanwhile, business development efforts continue.
18 juli, 08:42
Redeye comments on Annexin’s Q2 report and recent events in the company. Following the Q1 report, we implemented several updates to our model. With the Q2 figures now incorporated, only minor housekeeping adjustments have been made. The company is expected to initiate a phase IIa study in diabetes-induced retinopathy shortly, with potential for top-line data before year-end. Meanwhile, business development efforts continue.
Stockholmsbörsen
Skanska
Rapportperioden
Aktierekommendationer
Swedbank
Stockholmsbörsen
Skanska
Rapportperioden
Aktierekommendationer
Swedbank
1 DAG %
Senast
Boliden
18 juli, 17:55
Många stora kursrörelser efter rapporter
Kryptovalutor
18 juli, 16:09
Stablecoin i USA godkänns av senaten – kryptochefen: "Det här är superpositivt!"
Rapporter
18 juli, 15:27
Rapportfokus: SSAB, Sinch och SCA i rampljuset
OMX Stockholm 30
1 DAG %
Senast
2 546,70